PM
IMDX

Penbrook Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Penbrook Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,384
Closed -$73.6K – 102
2023
Q1 		$73.6K Hold
10,384
– – 0.06% 94
2022
Q4 		$66.6K Sell
10,384
-17,784
-63% -$196K 0.06% 94
2022
Q3 		$411K Sell
28,168
-620
-2% -$10.7K 0.35% 70
2022
Q2 		$518K Sell
28,788
-120
-0.4% -$2.73K 0.41% 65
2022
Q1 		$861K Hold
28,908
– – 0.56% 55
2021
Q4 		$1.25M Buy
28,908
+48
+0.2% +$2.76K 0.76% 41
2021
Q3 		$2.06M Buy
28,860
+7,771
+37% +$714K 1.28% 20
2021
Q2 		$2.42M Sell
21,089
-100
-0.5% -$9.76K 1.45% 15
2021
Q1 		$2.2M Hold
21,189
– – 1.58% 14
2020
Q4 		$1.01M Buy
21,189
+9,718
+85% +$357K 0.78% 45
2020
Q3 		$319K Buy
11,471
+690
+6% +$19.8K 0.28% 80
2020
Q2 		$412K Hold
10,781
– – 0.41% 70
2020
Q1 		$529K Buy
10,781
+1,937
+22% +$95K 0.68% 43
2019
Q4 		$398K Buy
+8,844
New +$319K 0.39% 75

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Penbrook Management's IMDX Position: Q2 2023 in Review

Penbrook Management sold out of Insight Molecular Diagnostics (IMDX) in Q2 2023, closing a stake of 10,384 shares — an estimated $73.6K sold.

Penbrook Management first reported a position in IMDX in Q4 2019 and held it in 14 quarters. The position peaked at $2.42M in Q2 2021. 47 funds tracked by Wall St. Rank hold IMDX as of Q2 2023.

  • Penbrook Management reported no remaining Insight Molecular Diagnostics position as of Q2 2023 after selling out during the quarter.
  • Penbrook Management sold 10,384 Insight Molecular Diagnostics shares in Q2 2023, an estimated $73.6K.
  • Penbrook Management first reported a position in Insight Molecular Diagnostics in Q4 2019 and held it in 14 quarters.
  • Penbrook Management's Insight Molecular Diagnostics position peaked at $2.42M in Q2 2021.
  • 47 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2023.

Based on Penbrook Management's 13F filing for Q2 2023, filed 17 Jul 2023.